# FLAME (NCT04769388)

> Osimertinib Plus Chemotherapy vs Osimertinib in EGFRm NSCLC With Persistence Week-3 ctDNA EGFRm After 1L Osimertinib

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04769388
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: Beijing Cancer Prevention & Treatment Society
- Conditions: Non Small Cell Lung Cancer
- Interventions: Osimertinib; Pemetrexed/Carboplatin
- Enrollment: 80
- Primary outcome: Progression free survival

## Commentary we found

- X threads: 3

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=flame-nct04769388